This listing of the claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-14. (cancelled).

15. (withdrawn) A method of treating obstructive airways diseases, wherein the diseases are selected from the group consisting of chronic obstructive pulmonary disease, adult respiratory distress syndrome, sepsis syndrome, pneumonia, aspiration of gastric content, chest trauma, shock, burns, fat embolia, cardiopulmonary bypass, $O_2$ toxicity, haemorhagic pancreatitis, interstitial and bronchoalveolar inflammation comprising administering a therapeutically effective amount of valsartan of formula



to a patient in need thereof.

16. (withdrawn) The method of claim 15 wherein chronic obstructive pulmonary disease includes bronchitis, chronic bronchitis, emphysema, asthma, cystic fibrosis, interstitial lung disease, pulmonary vascular disease and increased resistance to airflow during forced expiration.

17. (withdrawn) A solid oral dosage form according to claim 8 comprising 20 to 65% of valsartan.

18. (withdrawn) A solid oral dosage form according to claim 9 comprising 20 to 65% of valsartan.

19 (withdrawn) A solid oral dosage form according to claim 10 comprising 20 to 65% of valsartan.

20. (withdrawn) A solid oral dosage form according to claim 8 comprising 20 to 360 mg of valsartan.

21. (withdrawn) A solid oral dosage form according to claim 9 comprising 20 to 360 mg of valsartan.

22. (withdrawn) A solid oral dosage form according to claim 10 comprising 20 to 360 mg of valsartan.

23. (withdrawn) A solid oral dosage form according to claim 11 comprising 20 to 360 mg of valsartan.

24. (withdrawn) A solid oral dosage form according to claim 8 comprising less than 13% of crospovidone.

25. (currently amended) A compressed tablet comprising valsartan, microcrystalline cellulose and crospovidone, wherein the weight ratio of valsartan to microcrystalline cellulose is from ~~2~~ 1.4:1 to ~~0.3~~ 1 : 1.

26. (cancelled).

27. (previously presented) A tablet according to claim 25 comprising less than 13 % by weight of crospovidone.

28. (currently amended) A tablet according to any one of claims 25, wherein the weight ratio of microcrystalline cellulose to crospovidone is from 7 : 1 to ~~2~~ 3.6: 1.

29. (cancelled).

30. (cancelled).

31. (previously presented) A tablet according to claim 25, wherein the tablet comprises more than 250 mg and up to 360 mg valsartan as an active agent.

32. (previously presented) A tablet according to claim 25, wherein the tablet comprises 320 mg valsartan as an active agent.

33. (previously presented) A tablet according to claim 25, comprising
40 mg of valsartan
27 mg of microcrystalline cellulose and
7.5 mg of crospovidone.

34. (previously presented) A tablet according to claim 25, comprising
80 mg of valsartan

54 mg of microcrystalline cellulose and
15 mg of crospovidone.

35. (previously presented) A tablet according to claim 25 comprising
160 mg of valsartan
108 mg of microcrystalline cellulose and
30 mg of crospovidone.

36. (previously presented) A tablet according to claim 25, comprising
320 mg of valsartan
216 mg of microcrystalline cellulose and
60 mg of crospovidone.

37. (cancelled).

38. (cancelled).

39 (new) A compressed tablet comprising valsartan, more than 30% up to 65% by weight of microcrystalline cellulose, and less than 13% by weight of crospovidone.

40 (new) The tablet of claim 39 further comprising 20% to 65% by weight of valsartan.

41 (new) The tablet of claim 39 comprising:

20 to 65% by weight of valsartan
31% to 65% by weight of microcrystalline cellulose
2% to 10% by weight of crospovidone
1 to 10% by weight of magnesium stearate and
0.5% to 5% by weight of colloidal anhydrous silica.